Previous close | 924.00 |
Open | 924.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 924.00 - 925.00 |
52-week range | 9.25 - 948.05 |
Volume | |
Avg. volume | 1,679,225 |
Market cap | 1.234B |
Beta (5Y monthly) | 1.47 |
PE ratio (TTM) | 41.48 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.08 (0.82%) |
Ex-dividend date | 02 Dec 2021 |
1y target est | N/A |
LONDON, March 08, 2022-- FORM 8.5 (EPT/NON-RI)
BURLINGAME, Calif. & DUBLIN & LONDON, February 10, 2022--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program ("LenzMAP™"). Clinigen Group plc ("Clinigen"), a global pharmaceutical Services and Products company, is implementing the program. Lenzilumab